Category: CBSA News

Invenux Accelerates Solutions for the Future of Rare Disease Patients

By: Colorado BioScience Association   Date: 06/24/2022

Invenux, LLC, a privately held clinical stage biopharmaceutical company, is propelling its research and clinical trials forward to treat sickle cell disease in the U.S. and worldwide. By developing a...

Learn More

Manager’s Amendment in FDA Safety and Landmark Advancements (FDASLA) Act Would Include and Allow Drug Importation

By: Colorado BioScience Association   Date: 06/24/2022

Earlier this month, Colorado BioScience Association (CBSA) engaged on the U.S. Food and Drug Administration’s (FDA) Safety and Landmark Advancements (FDASLA) Act. CBSA and our national partners suppor...

Learn More

Weekly Policy Update: CBSA Engages on FDA Safety and Landmark Advancements (FDASLA) Act

By: Colorado BioScience Association   Date: 06/17/2022

Colorado BioScience Association (CBSA) and our national partners support the critically important reauthorization of the U.S. Food and Drug Administration’s (FDA) prescription drug, generic drug, bios...

Learn More

Colorado Governor Jared Polis Signs Reauthorization and Expansion of Advanced Industries Tax Credit Into Law

By: Colorado BioScience Association   Date: 06/03/2022

Colorado BioScience Association thanks Governor Jared Polis for signing the Advanced Industries Tax Credit, House Bill 1149, into law. “This legislation supports the incredible breakthroughs driving C...

Learn More

Colorado BioScience Association Applauds the 2022 Class of Boettcher Investigators

By: Colorado BioScience Association   Date: 06/01/2022

Boettcher Foundation awards $1.88 million in biomedical research grant funding to Colorado researchers DENVER, June 1, 2022 — Colorado BioScience Association (CBSA) congratulates the 2022 class of Boe...

Learn More

Validus Cellular Therapeutics Gains Momentum in Cellular Therapy

By: Colorado BioScience Association   Date: 05/27/2022

Validus Cellular Therapeutics, Inc. is pioneering the use of cellular therapy for the treatment of drug-resistant, chronic bacterial infections. Cellular therapy approaches have been successful for on...

Learn More

Weekly Policy Update: Small Business Innovation Research and Small Business Technology Transfer Programs Update

By: Colorado BioScience Association   Date: 05/27/2022

A longstanding policy priority for CBSA is supporting our ecosystem’s need for increased access to capital. Through our Capital + Growth efforts, we work closely with public and private partners to ac...

Learn More

Historic $200 Million Commitment to the University of Colorado Anschutz Medical Campus Fuels Advancements in Treatments and Cures

By: Colorado BioScience Association   Date: 05/25/2022

The University of Colorado Anschutz Medical Campus today announced the creation of the Gates Institute, a state-of-the-art facility that will focus on rapidly translating laboratory findings...

Learn More

Innosphere Ventures, Colorado BioScience Association, and Colorado BioScience Institute Announce the Colorado Life Sciences Incubation Program 2022 Cohort

By: Colorado BioScience Association   Date: 05/23/2022

Early-Stage Companies in Biotech, Medical Device, Oral Health/Teledentistry, and Health Technology Selected to Take Part in Year-Long, State-Funded Program Denver and Fort Collins, Colo.- Innosphere V...

Learn More

CBSA Congratulates Advanced Industries Accelerator Grant Recipients

By: Colorado BioScience Association   Date: 05/20/2022

Colorado’s Office of Economic Development and International Trade (OEDIT) announced the newest recipients of state-funded Advanced Industries Accelerator Grants this week. Colorado BioScience Associat...

Learn More